These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2476620)

  • 1. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
    Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
    Greenberg S; Touhey B
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.
    Perreault CL; Hague NL; Loh E; Hunneyball IM; Sim MF; Morgan JP
    Br J Pharmacol; 1992 Jul; 106(3):511-6. PubMed ID: 1324072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of flosequinan (BTS 49465) on myocardial oxygen consumption.
    Greenberg S; Touhey B; Paul J
    Am Heart J; 1990 Jun; 119(6):1355-66. PubMed ID: 2353621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium.
    Miao L; Perreault CL; Travers KE; Morgan JP
    Eur J Pharmacol; 1997 Feb; 321(2):201-8. PubMed ID: 9063689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes.
    Kelso EJ; McDermott BJ; Silke B
    J Cardiovasc Pharmacol; 1995 Mar; 25(3):376-86. PubMed ID: 7769801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular pharmacology of ICI 170777 ((6RS)-6-methyl-5-(pyrid-4-yl)-3H,6H-1,3,4- thiadiazin-2-one) a novel compound with positive inotropic and vasodilator effects.
    Collis MG; Keddie JR; Rouse W
    Br J Pharmacol; 1989 Jun; 97(2):409-18. PubMed ID: 2758224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of flosequinan's direct effect on human arterial, venous, and cardiac muscle: comparison with other classes of agents used to treat heart failure.
    Weishaar RE; Wallace AM; Kiser LM; Ferraris VA; Britton LW; Sim MF
    J Cardiovasc Pharmacol; 1994 May; 23(5):792-8. PubMed ID: 7521463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart.
    Yano M; Kohno M; Yamamoto T; Hisaoka T; Tanigawa T; Ono K; Lee B; Konishi M; Matsuzaki M
    J Cardiovasc Pharmacol; 1998 Sep; 32(3):466-70. PubMed ID: 9733361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flosequinan: a vasodilator with positive inotropic activity.
    Corin WJ; Monrad ES; Strom JA; Giustino S; Sonnenblick ES; LeJemtel T
    Am Heart J; 1991 Feb; 121(2 Pt 1):537-40. PubMed ID: 1990760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between inotropic activity and phosphodiesterase inhibition for flosequinan and milrinone.
    Weishaar RE; Kirker ML; Wallace AM; Ferraris VA; Britton LW; Sim MF
    Eur J Pharmacol; 1993 Jun; 236(3):363-6. PubMed ID: 8395383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo effects of amrinone and milrinone on left ventricular dP/dt, intraventricular pressure and heart rate in pentobarbital-anesthetized guinea pigs.
    Lin BB; Chen HL
    Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):237-40. PubMed ID: 1811284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
    Haas GJ; Binkley PF; Carpenter JA; Leier CV
    Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of the bipyridines: amrinone and milrinone.
    Alousi AA; Johnson DC
    Circulation; 1986 Mar; 73(3 Pt 2):III10-24. PubMed ID: 2417744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties.
    Mochizuki N; Uchida S; Miyata H
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):983-95. PubMed ID: 7687727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.